SANTIAGO, May 18 — An updated study showed that the CoronaVac vaccine developed by Chinese pharmaceutical firm Sinovac is 65.3 per cent efficacious in preventing COVID-19, Xinhua news agency quoted Chile’s Health Ministry on Monday.
“With at least four months of follow-up, we have super reliable and positive numbers,” said Dr Rafael Araos, an advisor to the Undersecretariat of Public Health, adding that data obtained over the period are “consistent.”
Despite the COVID-19 variants in circulation, “the vaccine is performing adequately,” he told reporters at a press conference.
The latest information updates the results of a previous study, titled “Effectiveness of the inactivated CoronaVac vaccine against SARS-CoV-2 in Chile,” which Araos presented on April 16, and follows the monitoring of another 10.2 million people up to May 1.
The vaccine’s efficacy in preventing hospitalisation rose to 87 per cent; in preventing admission to an intensive care unit (ICU), to 90.3 per cent; and in preventing deaths caused by COVID-19, to 86 per cent, according to Araos.
Also present was Chilean Deputy Minister of Public Health, Paula Daza, who stressed “the importance of all of us getting vaccinated. The vaccines that we have in the country are effective and we have seen it with the results in how symptomatic cases, hospitalizations, admissions to intensive care units and deaths decline.”
Daza urged those under 50 years of age to get vaccinated when their turns come, noting that the rate of immunisation is lower among younger people.
“We must reach 80 per cent of the target population in each age group,” she said, referring to the government’s goal of immunising 15 million people, about 80 per cent of Chile’s population, to achieve so-called herd immunity.
As of Sunday, a total of 9,074,158 people have been vaccinated against COVID-19 in Chile, with 7,491,484 completing both shots.
